Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of TYRA-300-B01 in Healthy Adults
NCT06006702Phase 1Active, not recruiting
- Sponsor
- Tyra Biosciences
- Start
- Oct 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dabogratinib in urothelial carcinoma (UC) and solid tumor (4 arms), sponsored by Tyra Biosciences. Primary endpoints: Pharmacokinetics single-dose Cmax, Pharmacokinetics multiple-dose Cmax and 8 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
dabogratinib
03
Conditions
urothelial carcinoma (UC)solid tumor
Beyond the preview
Go deeper on NCT06006702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006702.